137 related articles for article (PubMed ID: 22108625)
1. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity.
Bakheit AM; Liptrot A; Newton R; Pickett AM
Int J Rehabil Res; 2012 Mar; 35(1):36-9. PubMed ID: 22108625
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin A: dose and immune response.
Bigalke H; Frevert J
Int J Rehabil Res; 2012 Jun; 35(2):93. PubMed ID: 22561214
[No Abstract] [Full Text] [Related]
3. Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review.
Mathevon L; Declemy A; Laffont I; Perennou D
Ann Phys Rehabil Med; 2019 Jul; 62(4):241-251. PubMed ID: 30980953
[TBL] [Abstract][Full Text] [Related]
4. Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study.
Hefter H; Brauns R; Ürer B; Rosenthal D; Albrecht P
J Neurol; 2020 May; 267(5):1340-1347. PubMed ID: 31960136
[TBL] [Abstract][Full Text] [Related]
5. Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength.
Williams SA; Elliott C; Valentine J; Gubbay A; Shipman P; Reid S
Disabil Rehabil; 2013 Apr; 35(7):596-605. PubMed ID: 22928803
[TBL] [Abstract][Full Text] [Related]
6. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy.
Intiso D; Simone V; Di Rienzo F; Iarossi A; Pazienza L; Santamato A; Maruzzi G; Basciani M
NeuroRehabilitation; 2014; 34(3):515-22. PubMed ID: 24473245
[TBL] [Abstract][Full Text] [Related]
7. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles.
Bakheit AM; Fedorova NV; Skoromets AA; Timerbaeva SL; Bhakta BB; Coxon L
J Neurol Neurosurg Psychiatry; 2004 Nov; 75(11):1558-61. PubMed ID: 15489387
[TBL] [Abstract][Full Text] [Related]
8. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF
Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.
Kaňovský P; Slawek J; Denes Z; Platz T; Comes G; Grafe S; Pulte I
J Rehabil Med; 2011 May; 43(6):486-92. PubMed ID: 21533328
[TBL] [Abstract][Full Text] [Related]
11. Clinical resistance to three types of botulinum toxin type A in aesthetic medicine.
Stephan F; Habre M; Tomb R
J Cosmet Dermatol; 2014 Dec; 13(4):346-8. PubMed ID: 25399628
[TBL] [Abstract][Full Text] [Related]
12. Motor endplate-targeted botulinum toxin injections of the gracilis muscle in children with cerebral palsy.
Van Campenhout A; Bar-On L; Desloovere K; Huenaerts C; Molenaers G
Dev Med Child Neurol; 2015 May; 57(5):476-83. PubMed ID: 25557985
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.
Müller K; Mix E; Adib Saberi F; Dressler D; Benecke R
J Neural Transm (Vienna); 2009 May; 116(5):579-85. PubMed ID: 19352590
[TBL] [Abstract][Full Text] [Related]
14. Intrafusal effects of botulinum toxin in post-stroke upper limb spasticity.
Trompetto C; Bove M; Avanzino L; Francavilla G; Berardelli A; Abbruzzese G
Eur J Neurol; 2008 Apr; 15(4):367-70. PubMed ID: 18266870
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
16. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications.
Dressler D; Wohlfahrt K; Meyer-Rogge E; Wiest L; Bigalke H
Dermatol Surg; 2010 Dec; 36 Suppl 4():2182-7. PubMed ID: 21134050
[TBL] [Abstract][Full Text] [Related]
17. [Use of botulinum neurotoxin for spasticity].
Mukai Y; Kaji R
Brain Nerve; 2008 Dec; 60(12):1421-6. PubMed ID: 19110753
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients.
Mohammadi B; Balouch SA; Dengler R; Kollewe K
Neurol Res; 2010 Apr; 32(3):309-13. PubMed ID: 19726016
[TBL] [Abstract][Full Text] [Related]
19. Do flexible inter-injection intervals improve the effects of botulinum toxin A treatment in reducing impairment and disability in patients with spasticity?
Trompetto C; Marinelli L; Mori L; Puce L; Pelosin E; Serrati C; Fattapposta F; Rinalduzzi S; Abbruzzese G; Currà A
Med Hypotheses; 2017 May; 102():28-32. PubMed ID: 28478825
[TBL] [Abstract][Full Text] [Related]
20. Results of a BoNT/A antibody study in children and adolescents after onabotulinumtoxin A (Botox®) detrusor injection.
Schulte-Baukloh H; Herholz J; Bigalke H; Miller K; Knispel HH
Urol Int; 2011; 87(4):434-8. PubMed ID: 21967991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
